Stories from people navigating Chronic Kidney Disease — diagnosis, treatment, caregiving, and the ordinary days in between.
12 stories
Endocrinology & Metabolism
The FDA has approved finerenone for renal protection in adults with type 1 diabetes and chronic kidney disease, using albuminuria reduction as the basis for the new pathway.
Rayan Salih · November 9, 2026 · 6 min
Cardiology
A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.
Rayan Salih · 7 min read
Cardiology
The 2026 CKM guideline calls for earlier, integrated prevention when cardiovascular, kidney and metabolic risks coexist, with action spanning primary care, endocrinology, nephrology and cardiology.
Dr. Abu Bakar · 7 min read
Cardiology
The 2026 multisociety guideline defines a unified pathway for evaluating cardiovascular, kidney and metabolic risk, particularly when disease or risk factors overlap.
Rayan Salih · 7 min read
Endocrinology & Metabolism
A secondary analysis found that finerenone reduced cardiovascular and kidney events across CKM stages in adults with type 2 diabetes and CKD, while favoring CKM stage regression over progression.
Dr. Abu Bakar · 7 min read
Endocrinology & Metabolism
Updated evidence supports SGLT inhibition across heart failure phenotypes, with the clearest benefit in preventing worsening heart failure. Mortality and safety findings require more nuanced interpretation.
Dr. Abu Bakar · 7 min read
Health Policy
The 2026 joint guideline links lipid management to CKM stage and PREVENT-ASCVD risk, with explicit LDL-C, non-HDL-C and apoB goals for US adults.
Rayan Salih · 7 min read
Cardiology
The 2026 guideline retains a 130/80 mm Hg diagnostic threshold but links medication timing to cardiovascular, diabetes and kidney risk. Most treated adults share a target below 130/80 mm Hg.
Rayan Salih · 7 min read
Clinical Briefs
In FLOW, semaglutide reduced major kidney outcomes and cardiovascular death among adults with type 2 diabetes and albuminuric chronic kidney disease.
Rayan Salih · 6 min read
Health Policy
Chronic kidney disease (CKD) screening via mobile health units is emerging as a practical way to reach people
Dr. Abu Bakar · 7 min read
Cardiology
Pheochromocytoma is a rare, life-threatening tumor of the adrenal glands that can cause sudden surges of stress hormones
Dr. Abu Bakar · 9 min read
Cardiology
Management of lipid levels in patients with chronic kidney disease (CKD), human immunodeficiency virus (HIV) infection, and cancer
Dr. Abu Bakar · 15 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.